For decades, Parkinson’s disease has been framed as a simple story of dwindling dopamine, a slow erosion of the brain’s ...

Abbvie ($ABBV) announced an update on their ongoing clinical study. AbbVie has announced a new clinical study titled ‘A ...

A McGill-led study is challenging a popular theory about how dopamine drives movement, a discovery that could shift how ...

The U.S. Food and Drug Administration is reviewing a new Parkinson’s disease drug called tavapadon that could give people with the disease more control over their movements. If approved, it would be ...

Keith Krehbiel lived with Parkinson’s disease for nearly 25 years before agreeing to try a brain implant that might alleviate his symptoms. He had long been reluctant to submit to the surgery. “It was ...

A new weekly injectable drug could transform the lives of more than eight million people living with Parkinson’s disease, potentially replacing the need for daily pills. Scientists from the University ...

A new study from McGill University challenges a decades-old belief about dopamine. Rather than driving movement like a ...

Parkinson’s disease currently affects nearly one million Americans with no specific known cause and no cure. Treatments have come a long way over the past few decades focusing on managing symptoms and ...

Van Andel Institute and Cure Parkinson’s have renewed a funding agreement to support the International Linked Clinical Trials Program, the world’s largest drug repurposing clinical trial initiative ...

Explore dopamine's role in movement and how it challenges long-standing theories about motor control and Parkinson's disease ...

The actor, advocate and author of the new book 'Future Boy' opens up in the latest issue of PEOPLE Eric Andersson joined PEOPLE as a senior writer in 2022. His work has appeared in TV Guide Magazine, ...

A new study shows dopamine isn’t the brain’s movement “gas pedal” after all. Instead of setting speed or strength, it quietly ...